Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies.

Critical reviews in oncology/hematology - 1 Feb 2020

Giopanou Ioanna, Pintzas Alexandros

Abstract excerpt

Lung and colorectal cancer are included in the most tremendously threatening diseases in terms of incidence and death. Although they are located in completely different organs and differ in various characteristics they do share some common features, especially regarding their molecular mutational profile. Among several commonly mutated genes KRAS and BRAF are spotted to be highly associated with patient's poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Colorectal Neoplasms

Share to Disease Progression

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Source

Identifiers

PMID: 31927392
DOI: 10.1016/j.critrevonc.2019.102859

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies.PMID 31927392Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Novel insights into the molecular origins and treatment of lung cancer.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health.Semantic proximity Read ↗

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.Semantic proximity Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.